Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. - sprookjes - yvandenbroek - TriplyDB

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q53493942

about

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.How to manage the transplant question in myelofibrosis.Rational therapeutic options for patients with myeloproliferative neoplasms.Allogeneic stem cell transplantation for myelofibrosis in 2012.How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome.Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis.Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

P2860

Q33643387-5A8BEF4D-630E-40F8-B6A1-A8447C5A6E89 Q33771667-F4A5ED06-7D31-47B4-B668-AC09BDECE174 Q34047897-1028045C-D925-42A5-A66B-ACDE4880968E Q34625390-B45CAFDF-F4B0-49B4-8C4F-F74E3A08AABF Q35865676-AC4C5DB6-32DE-4B69-A1FD-EC55CB9C9431 Q37891692-47611472-CD2B-45C2-B327-B8215B5931D6 Q37998567-A1025586-2437-4374-84DC-D4204063AEA4 Q38254425-8969C3B5-7D62-4150-81F6-3647ABAF537B Q38569146-89894F09-7239-401C-8F1A-41C34932E450 Q38570614-76FB32B9-F7FC-4264-B157-B1F9E8957256 Q38603384-B08B8E3E-C7CB-4464-B217-DA51EB47CD3A Q39811454-11C60901-A9AF-4765-A4B0-9D9720014CAC Q40453557-9353918E-C78D-4051-A741-B733592FDE68 Q43162409-CB4626BE-0342-4A86-866E-FF1834F2A85E Q45060240-18BDEE5B-8F5D-40C2-8024-54C49DA95FBF Q47174502-0CE1712A-7503-45AA-8C88-15456FF2E47E Q50965749-FDBFE473-2EBC-41A0-9954-24366CCD2572 Q54374933-0320DE90-D07E-46BE-BD6E-110EDB4B439A

P2860

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q53493942

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Effects of extensive splenomeg ...... eic stem cell transplantation.

@en

Effects of extensive splenomeg ...... eic stem cell transplantation.

@nl

type

label

Effects of extensive splenomeg ...... eic stem cell transplantation.

@en

Effects of extensive splenomeg ...... eic stem cell transplantation.

@nl

prefLabel

Effects of extensive splenomeg ...... eic stem cell transplantation.

@en

Effects of extensive splenomeg ...... eic stem cell transplantation.

@nl

P1433

Q53493942-9D478C00-3064-4E3C-9683-17C6DADED532

P1476

Q53493942-81148CEE-1E53-4635-99C3-128BDACEE8DC

P2093

Q53493942-0814EA62-F1F2-4345-BC09-AB2DDE1AD59D

Q53493942-0DC7BBEF-E122-4B17-AFFF-A499B92AC9B4

Q53493942-24AFE443-957D-4C3C-B660-3545D3C87672

Q53493942-2A1D11D4-D7A4-453B-BDF0-00867C61D9D9

Q53493942-332CF37A-54F3-425B-BDA3-D400B1D8F62B

Q53493942-A5E32DE1-9C63-4D07-96C1-A7CEB613B48C

Q53493942-A78C15B6-B8D7-41CB-BD9D-C11FDB99544E

Q53493942-C1FC9041-5EDB-4779-841C-6DCD2C580DF3

Q53493942-D07BCA16-22AD-4AA4-B223-B79B92751728

P2860

Q53493942-6D00BF7D-D2EB-4395-B194-1BAECA5DAF2A

Q53493942-7168337A-9636-4842-BB18-11F999BB288A

Q53493942-897DB640-A4EA-43BB-ACF2-160BB684D4E2

Q53493942-B1BA88E3-6140-49CB-9422-A060F8BD31C9

Q53493942-C8295B3F-DA5D-4BCD-BEA9-B66A04AFBABD

Q53493942-DF1747EB-C8B6-432E-BF58-1FAA9363DFDF

Q53493942-EF369491-30F4-421C-B8B6-8EC72CE7EB69

P304

Q53493942-77AE8D8A-EE08-428F-AA1E-8D10B45D1010

P31

Q53493942-AF401438-A554-487E-9328-11E14B983616

P356

Q53493942-4B62C010-86FF-4734-98D6-79D558AF4A6F

P407

Q53493942-3950AC8D-C40D-4DFA-81E6-950733E07201

P433

Q53493942-DFFE6CDA-BCA3-4C57-B015-B1325CE11742

P478

Q53493942-00445BDF-CD3B-42B1-826A-CB0E95B0D1FD

P577

Q53493942-614C491E-88F1-44B5-9D99-786B408D08C6

P5875

Q53493942-21B1E534-1A07-423A-B931-F148860B834A

P698

Q53493942-6B9CAD70-D613-4641-858F-9EE62362CE60

P356

J.1365-2141.2008.07010.X

P1433

British Journal of Haematology

P1476

Effects of extensive splenomeg ...... eic stem cell transplantation.

@en

P2093

Andrew Wilbur

http://www.w3.org/2001/XMLSchema#string

Barry Sadegi

http://www.w3.org/2001/XMLSchema#string

Damiano Rondelli

http://www.w3.org/2001/XMLSchema#string

Lisa C Dobogai

http://www.w3.org/2001/XMLSchema#string

Luke P Akard

http://www.w3.org/2001/XMLSchema#string

Ronald Hoffman

http://www.w3.org/2001/XMLSchema#string

Stefan O Ciurea

http://www.w3.org/2001/XMLSchema#string

Sujata Gaitonde

http://www.w3.org/2001/XMLSchema#string

Victoria Alagiozian-Angelova

http://www.w3.org/2001/XMLSchema#string

P2860

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.

Determination of splenomegaly by CT: is there a place for a single measurement?

Estimating splenic volume: sonographic measurements correlated with helical CT determination.

P304

80-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2008.07010.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5527320

http://www.w3.org/2001/XMLSchema#string

P698

18324970

http://www.w3.org/2001/XMLSchema#string